Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction

Angiotensin receptor-neprilysin inhibitor (ARNI) and sodium–glucose co-transporter-2 inhibitor (SGLT2i) have shown benefits in diabetic patients with heart failure with reduced ejection fraction (HFrEF). However, their combined effect has not been revealed. We retrospectively identified diabetic pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyue Mee, Hwang, In-Chang, Choi, Wonsuk, Yoon, Yeonyee E., Cho, Goo-Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595580/
https://www.ncbi.nlm.nih.gov/pubmed/34785723
http://dx.doi.org/10.1038/s41598-021-01759-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595580/
https://www.ncbi.nlm.nih.gov/pubmed/34785723
http://dx.doi.org/10.1038/s41598-021-01759-5

Ejemplares similares